- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Brodalumab significantly improves Depression in Psoriasis Patients
A recent study published in The Journal of Dermatology found a promising treatment avenue for individuals battling psoriasis alongside the often accompanying emotional burden of depression and anxiety. The study by Ylva Andersch-Björkman and team evaluated the emotional well-being of psoriatic patients who had undergone a treatment switch from tumor necrosis factor-alpha inhibition (TNF-α) to interleukin 17 inhibition using brodalumab due to insufficient responses.
Psoriasis is a chronic skin condition that often comes with emotional tolls such as depression and anxiety. Managing these mental health aspects alongside the physical symptoms of psoriasis is crucial for overall patient well-being.
The study, conducted over a span of 3 months, included 20 patients with psoriasis. To gauge the emotional impact of the transition to brodalumab treatment, researchers employed the Self-rated Montgomery-Asberg Depression Rating Scale and the Hospital Anxiety and Depression Scale. The results were nothing short of remarkable.
First and foremost, the study reported a significant improvement in the Psoriasis Area and Severity Index (PASI) scores, indicating a tangible reduction in psoriatic lesions and severity. However, what truly captivated the researchers was the substantial improvement in symptoms of depression.
While anxiety symptoms showed a reduction, they did not reach statistical significance, hinting at a potential avenue for further research. Nevertheless, the newfound positive effects on depression and anxiety seemed to operate independently of the reduction in psoriatic lesions. This suggests that the treatment might possess a unique quality in addressing the emotional aspects of psoriasis.
These findings underscore the importance of holistic patient care when dealing with psoriasis. Psoriasis isn't just skin deep; it affects the emotional and psychological well-being of patients. Brodalumab, with its potential to alleviate both physical and emotional symptoms, could revolutionize psoriasis management.
Reference:
Andersch‐Björkman, Y., Micu, E., Seifert, O., Lonne‐Rahm, S., Gillstedt, M., & Osmancevic, A. (2023). Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF‐α inhibitors. In The Journal of Dermatology. Wiley. https://doi.org/10.1111/1346-8138.16917
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751